Bone marrow micrometastases and circulating tumor cells: Current aspects and future perspectives

Breast Cancer Research

Volumn 6, Issue 6, 2004, Pages 258-261

  Müller, Volkmar ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Blood; Bone marrow; Breast cancer; Disseminated tumor cells

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN 19;

ARTICLE; BONE MARROW METASTASIS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CHROMOSOME ABERRATION; CLINICAL TRIAL; DRUG EFFICACY; GENE MUTATION; GENETIC ANALYSIS; HUMAN; IMMUNOASSAY; IMMUNOCYTOCHEMISTRY; POLYMERASE CHAIN REACTION; PREDICTION; PROGNOSIS; SYSTEMIC THERAPY; TREATMENT OUTCOME; TUMOR CELL;

BONE MARROW NEOPLASMS; BREAST NEOPLASMS; HUMANS; NEOPLASM CIRCULATING CELLS;

EID: 7444245527     PISSN: 14655411     EISSN: None     Source Type: Journal    
DOI: 10.1186/bcr942     Document Type: Article

References (25)

1. Pantel K, Brakenhoff RH: Dissecting the metastatic cascade. Nat Rev Cancer 2004, 4:448-456.
2. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, et al.: Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342:525-533.
3. Diel IJ, Kaufmann M, Costa SD, Holle R, von Minckwitz G, Solomayer EF, Kaul S, Bastert G: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst 1996, 88: 1652-1658.
4. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W: Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 2001, 19:3669-3674.
5. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger IJ, Coombes RC: Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 1999, 354:197-202.
6. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, et al.: Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 2003, 21: 3469-3478.
7. Pierga JY, Bonneton C, Vincent-Salomon A, de Cremoux P, Nos C, Blin N, Pouillart P, Thiery JP, Magdelenat H: Clinical significance of immunocytochemical detection of tumor cells using digital microscopy in peripheral blood and bone marrow of breast cancer patients. Clin Cancer Res 2004, 10:1392-1400.
8. Braun S, Vogl FD, Schlimok G, Diel I, Janni W, Gerber B, Gebauer G, Coombes RC, Pierga JY, Naume B, et al.: Pooled analysis of prognostic impact of bone marrow micrometastasis: 10-year survival of 4199 breast cancer patients. Breast Cancer Res Treat 2003, 82 Suppl 1:S8.
9. Naume B, Wiedswang G, Borgen E, Kvalheim G, Karesen R, Qvist H, Janbu J, Harbitz T, Nesland JM: The prognostic value of isolated tumor cells in bone marrow in breast cancer patients: evaluation of morphological categories and the number of clinically significant cells Clin Cancer Res 2004, 10:3091-3097.
10. Janni W, Hepp F, Rjosk D, Kentenich C, Strobl B, Schindlbeck C, Hantschmann P, Sommer H, Pantel K, Braun S: The fate and prognostic value of occult metastatic cells in the bone marrow of patients with breast carcinoma between primary treatment and recurrence. Cancer 2001, 92:46-53.
11. Wiedswang G, Borgen E, Karensen R, Qvist H, Naume B: The presence of isolated tumor cells in bone marrow three years after diagnosis in disease free breast cancer patients predicts an unfavorable outcome. Breast Cancer Res Treat 2003, 82 Suppl 1:S8.
12. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, et al.: A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003, 349:1793-1802.
13. Mehes G, Witt A, Kubista E, Ambros PF: Circulating breast cancer cells are frequently apoptotic. Am J Pathol 2001, 159: 17-20.
14. Terstappen LW, Rao C, Gross S, Weiss AJ: Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 2000, 17: 573-578.
15. Smith BM, Slade MJ, English J, Graham H, Luchtenborg M, Sinnett HD, Cross NC, Coombes RC: Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocytochemical techniques. J Clin Oncol 2000, 18:1432-1439.
16. Stathopoulou A, Vlachonikolis I, Mavroudis D, Perraki M, Kouroussis C, Apostolaki S, Malamos N, Kakolyris S, Kotsakis A, Xenidis N, et al.: Molecular detection of cytokeratin-19-positive cells in the peripheral blood of patients with operable breast cancer: evaluation of their prognostic significance. J Clin Oncol 2002, 20:3404-3412.
17. Weigelt B, Bosma AJ, Hart AA, Rodenhuis S, van 't Veer LJ: Marker genes for circulating tumour cells predict survival in metastasized breast cancer patients. Br J Cancer 2003, 88: 1091-1094.
18. Mueller V, Stahmann N, Zabel T, Goetz A, Jaenicke F, Thomssen C, Pantel K: Detection of circulating tumor cells in patients with primary and metastatic breast cancer by enhanced gradient centrifugation Breast Cancer Res Treat 2003, 82 Suppl 1: S94.
19. Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Matera J, Miller MC, Reuben JM, Doyle GV, Allard WJ, Terstappen LW, et al.: Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004, 351:781-791.
20. Mueller P, Carroll P, Bowers E, Moore D 2nd, Cher M, Presti J, Wessman M, Pallavicini MG: Low frequency epithelial cells in bone marrow aspirates from prostate carcinoma patients are cytogenetically aberrant. Cancer 1998, 83:538-546.
21. Fehm T, Sagalowsky A, Clifford E, Beitsch P, Saboorian H, Euhus D, Meng S, Morrison L, Tucker T, Lane N, et al.: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 2002, 8: 073-2084.
22. Solakoglu O, Maierhofer C, Lahr G, Breit E, Scheunemann P, Heumos I, Pichlmeier U, Schlimok G, Oberneder R, Kollermann MW, et al. Heterogeneous proliferative potential of occult metastatic cells in bone marrow of patients with solid epithelial tumors. Proc Natl Acad Sci USA 2002, 99:2246-2251.
23. Klein CA, Blankenstein TJ, Schmidt-Kittler O, Petronio M, Polzer B, Stoecklein NH, Riethmuller G: Genetic heterogeneity of single disseminated tumour cells in minimal residual cancer. Lancet 2002, 360:683-689.
24. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 2003, 100:7737-7742.
25. Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, et al.: Revision of the American Joint Committee on Cancer staging system for breast cancer J Clin Oncol 2002, 20:3628-3636.